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Abstract
Background: Candida albicans, a commensal organism, is a part of the normal flora of healthy individuals. However, once
the host immunity is compromised, C. albicans opportunistically causes recurrent superficial or fatal systemic candidiasis.
Secreted aspartic proteases (Sap), encoded by 10 types of SAP genes, have been suggested to contribute to various
virulence processes. Thus, it is important to elucidate their biochemical properties for better understanding of the molecular
mechanisms that how Sap isozymes damage host tissues.
Methodology/Principal Findings: The SAP7 gene was cloned from C. albicans SC5314 and heterogeneously produced by
Pichia pastoris. Measurement of Sap7 proteolytic activity using the FRETS-25Ala library showed that Sap7 was a pepstatin A-
insensitive protease. To understand why Sap7 was insensitive to pepstatin A, alanine substitution mutants of Sap7 were
constructed. We found that M242A and T467A mutants had normal proteolytic activity and sensitivity to pepstatin A. M242
and T467 were located in close proximity to the entrance to an active site, and alanine substitution at these positions
widened the entrance. Our results suggest that this alteration might allow increased accessibility of pepstatin A to the active
site. This inference was supported by the observation that the T467A mutant has stronger proteolytic activity than the wild
type.
Conclusions/Significance: We found that Sap7 was a pepstatin A-insensitive protease, and that M242 and T467 restricted
the accessibility of pepstatin A to the active site. This finding will lead to the development of a novel protease inhibitor
beyond pepstatin A. Such a novel inhibitor will be an important research tool as well as pharmaceutical agent for patients
suffering from candidiasis.
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Introduction
The commensal organism Candida albicans exists in almost all
humans as a part of the natural microflora [1]. However, once the
host immunity is diminished or the balance of the normal
microflora is disrupted, C. albicans may turn opportunistic and
cause recurrent superficial or fatal systemic candidiasis. Superficial
candidiasis has a widespread occurrence, and three-quarters of
healthy women experience vaginal candidiasis [2,3]. In addition,
the mortality rate of systemic candidiasis is notably high because of
the lack of effective diagnosis and treatment. Thus, it is vital to
elucidate the virulence mechanisms of C. albicans and develop
novel pharmaceutical agents.
The secreted aspartic protease (Sap) family, encoded by 10 SAP
genes, has been suggested as one of the major virulence factors of
C. albicans [1,4,5,6]. SAP genes are differentially regulated
depending on the surrounding environments [7], and of the 10
SAP genes, the expression of SAP1–3 has been mainly observed in
the yeast forms [8]. Compared to them, SAP4–6 are expressed in
the hyphal forms, and are related to systemic infections and
evasion from the host immune system [9]. SAP7 expression has
been detected in mouse models, but not in any in vitro conditions,
and it correlates with virulence in intravenous infections [10].
SAP8 is transiently expressed in yeast and epithelial models
[11,12]. SAP9 and SAP10, which encode glycosylphosphatidyli-
nositol (GPI)-anchoring domains, are expressed under many
conditions, and are believed to maintain cell wall integrity
through the post-translational processing of cell wall proteins
[13,14,15].
All types of SAP gene products are suggested to contribute to
various virulence processes in vitro, such as adhesion, invasion, and
immune evasion. For example, they degrade host defense proteins
such as mucin [16], IgG [17], IgA [18], and complements (C3b,
C4b, and C5) [19]. Furthermore, Sap isozymes are needed to
obtain nitrogen from proteins [8], escape from macrophages [9],
and to adhere to and invade epithelial tissues [20,21].
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7In this study, we found that pepstatin A did not have any effect
on the proteolytic activity of Sap7. It was surprising because
pepstatin A generally inhibits all aspartyl proteases. We analyzed
the cause of Sap7 insensitivity toward pepstatin A, and found that
the core structure of Sap7 prohibited pepstatin A from accessing
the active site. This study paves the way for the development of a
novel, potent inhibitor that is able to inhibit all types of Sap
isozymes. Such an inhibitor might be a more effective pharma-
ceutical agent against candidiasis.
Materials and Methods
Strains and media
Escherichia coli strain DH5a [F
2, DlacU169 (w80lacZDM15),
hsdR17 (rK
2, mK
+), recA1, endA1, deoR, thi-1, supE44, gyrA96, relA1,
l
2] (TOYOBO, Osaka, Japan) was used as a host for DNA
manipulation. C. albicans strain SC5314 (American Type Culture
Collection) was used for isolation of the Candida genome. Pichia
pastoris strain GS115 [his4] (Invitrogen, CA, USA) was used as a
host for protein production. E. coli transformants were grown in
Luria–Bertani media [1% (w/v) tryptone, 0.5% (w/v) yeast extract,
and 1% (w/v) sodium chloride] containing 50 mg/mL ampicillin.
For protein production, P. pastoris transformants were pre-
cultivated in buffered complex glycerol media (BMGY) [1% (w/
v) yeast extract, 2% (w/v) peptone, 1.34% (w/v) yeast nitrogen base
w/o amino acids, (4610
25)% (w/v) biotin, and 1% (v/v) glycerol, in
100 mM potassium phosphate (pH 6.0)]. For transcriptional
induction, pre-cultivated transformants were grown in buffered
complex methanol media (BMMY) [1% (w/v) yeast extract, 2%
(w/v) peptone, 1.34% (w/v) yeast nitrogen base w/o amino acids,
(4610
25)% (w/v) biotin, 0.5% (v/v) methanol, and 100 mM
potassium phosphate (pH 6.0)].
Construction of plasmids encoding mutant Sap7
All the primers used in this study are presented in Table S1. In
the previous study, DNA fragments encoding the SAP4 and SAP7
genes were cloned from the genomic DNA extracted from C.
albicans SC5314, and were inserted into the pHIL-S1 plasmid
(Invitrogen) [22]. The resulting recombinant genes were composed
of the PHO1 secretion signal sequence, the SAP gene, and a
FLAG-tag encoding sequence. Because C. albicans displays
alternative CUG codon usage (Ser for Leu) [23], CUG codons
in the SAP genes were replaced by UCG codons, which encode Ser
in P. pastoris. The resulting plasmids were named pHIL-Sap4 and
pHIL-Sap7. To determine which amino acid was important for
insensitivity to pepstatin A, the target amino acids of Sap7 were
substituted with alanine. The SAP gene sequence was mutated by
the QuikChange site-directed mutagenesis technique by using 2
complementary primers. To construct pHIL-Sap7D422–451, 2
DNA fragments encoding 19–421 and 452–588 amino acid
residues of Sap7 were amplified. Then, these DNA fragments were
inserted into the pHIL-S1 vector by using In-Fusion HD Cloning
Kit (Clontech, CA, USA). The DNA sequences were verified using
BigDye Terminator v3.1 Cycle Sequencing Kit and 310 Genetic
Analyzer (Applied Biosystems, CA, USA).
Production and purification of FLAG-tagged Sap
isozymes
pHIL-Sap4, pHIL-Sap7, and pHIL-S1, a control plasmid,
were digested with SacI. P. pastoris GS115 cells were transformed
with the linear plasmids by using the Frozen-EZ Yeast
Transformation II kit (Zymo Research, CA, USA). The P. pastoris
transformant was grown in BMGY medium for 48 h at 30uC.
The culture medium was subsequently centrifuged at 3000 g for
5 min. The cells were resuspended in BMMY medium for
transcriptional induction, and then grown for 24 h at 30uC. The
supernatant of the culture medium was concentrated using a YM-
10 filter device (Millipore, MA, USA), and the concentrated
supernatant was mixed with an anti-FLAG M2 affinity gel
(Sigma-Aldrich, MO, USA) and rotated for 1 h at 4uC. The gel
was washed with PBS (pH 7.4) to remove non-specific proteins.
FLAG-tagged Sap isozymes were eluted from the gel by using a
36FLAG peptide (Sigma-Aldrich). The protein concentration
was quantified using the Protein Assay Bicinchoninate Kit
(Nacalai Tesque, Kyoto, Japan).
SDS-PAGE, CBB staining, and western blotting
The purified Sap isozymes were separated by SDS-PAGE with
or without EndoH (New England Biolabs, MA, USA) treatment in
a 5%–20% gradient polyacrylamide gel. The protein bands were
detected with the CBB Stain One kit (Nacalai Tesque) or western
blotting using the anti-FLAG M2 monoclonal antibody-peroxidase
conjugate (Sigma-Aldrich). To determine whether the 2 fragments
of Sap7 were bound to each other in a non-covalent manner, Sap7
was separated by SDS-PAGE without 2-mercaptoethanol treat-
ment and stained with CBB.
MALDI-TOF/MS analysis and N-terminal sequencing
The protein bands detected by CBB staining were identified
using a Voyager RP MALDI-TOF/MS (Applied Biosystems).
Amino acid sequencing of purified Sap isozymes was carried out
by the Edman degradation method on the protein sequence
system PPSQ-33A (Shimadzu, Kyoto, Japan), using a Hybond-P
membrane (GE Healthcare, Little Chalfont, UK).
Measurement of proteolytic activity
To determine the proteolytic activity of the Sap isozymes, the
FRETS-25Ala library (Peptide Institute, Osaka, Japan) was used as
a substrate as described previously [22]. In brief, the peptide
library (final concentration, 10 mM) was mixed with Sap4 as a
control or Sap7 (final concentration, 3 nM or 5 nM, respectively)
in 200 mL of sodium citrate buffer (50 mM; pH 6.0) at 37uC. The
increase in fluorescence was kinetically measured at lex=355 nm
and lem=460 nm. One unit of proteolytic activity was defined as
that increasing the fluorescence by 1 min
21 at optimum pH. For
inhibitory assays, pepstatin A (Peptide Institute), EDTA (DO-
JINDO, Kumamoto, Japan), leupeptin (Peptide Institute), or
phenylmethylsulfonyl fluoride (PMSF) (Peptide Institute) were
mixed with the reaction solution (final concentration, 1 mM,
1 mM, 4 mM, and 200 mM, respectively).
Protein sequence analysis
Protein sequences of Sap isozymes were obtained from the
Candida genome database [24]. Multiple-sequence alignments were
performed with CLUSTAL W [25].
Homology modeling
A structural model for Sap7 was generated using SWISS-
MODEL based on the crystal structure of Sap2 (PBD ID: 1eag)
[26,27]. The calculated Sap7 structure was verified using a
Ramachandran map generated by PDBSum [28], and visualized
using Pymol (DeLano Scientific; http://www.pymol.org).
Statistics
Mean values among groups were compared using one-way
factorial ANOVA, with P,0.05 being considered statistically
significant. If the ANOVA was significant, post-hoc pair wise
Sap7 Is Insensitive to Pepstatin A
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also being considered statistically significant.
Results
Biochemical properties of Sap7
The SAP7 gene with a C-terminal FLAG tag-encoding sequence
was cloned from the C. albicans SC5314 genome. The DNA
fragment was inserted into pHIL-S1, a vector for secretory protein
production by P. pastoris. The transformants were cultivated in
BMMY media for transcriptional induction, and the production of
FLAG-tagged Sap7 was examined by SDS-PAGE and western
blotting. Two distinct protein bands, a band around 60 kDa and a
smear band around 24 kDa, were observed as purified protein
extracts, while no band was detected in the control lane (Fig. 1A).
To check whether Sap7 was glycosylated, Sap7 was mixed with
EndoH that cleaves oligosaccharides from N-linked glycoproteins,
and incubated for 1 h at 37uC. Following treatment with EndoH,
these bands shifted to 52 kDa (fragment 1) and 15 kDa (fragment
2), and only the 15-kDa band was detected by western blotting
using an anti-FLAG monoclonal antibody. These results indicated
that Sap7 was a highly, heterogeneously N-glycosylated protein,
and was separated into 2 distinct fragments. To determine the
primary sequence of the fragments, these protein bands were
excised, and analyzed by MALDI-TOF/MS and N-terminal
sequencing. The analyses showed that fragment 1 was composed
of amino acids from A144 to G440, and fragment 2, from A441 to
E588 plus a C-terminal Flag-tag epitope (Fig. 1C). The region
from M1 to K143, a secretion signal sequence and a propeptide of
Sap7, was probably removed during a maturation process. In
addition, non-reducing SDS-PAGE was performed to determine
whether the fragments form a disulfide bond (Fig. 1B). The
electrophoretic pattern of the non-reduced SDS-PAGE did not
differ from that of the reduced SDS-PAGE. This result suggests
that the 2 fragments of Sap7 are bound to each other in a non-
covalent manner.
Measurement of proteolytic activity of Sap7
The proteolytic activity of Sap7 was determined in 50 mM
sodium citrate buffer (pH 6.0) at 37uC using the FRETS-25Ala
Figure 1. Biochemical characteristics of Sap7. (A) SDS-PAGE (left) and western blot (right) analysis of Sap7 with or without EndoH treatment.
Analyses of all bands by MALDI-TOF/MS and N-terminal sequencing showed that Sap7 consisted of 2 fragments: fragment 1 (52 kDa) and fragment 2
(15 kDa). Fragment 2 was highly, heterogeneously N-glycosylated, as revealed by EndoH treatment and western blot analysis, which detected the
FLAG-tag epitope conjugated at the C-terminal end of Sap7. M: marker, control: protein extracted from the culture supernatant of P. pastoris
transformed with a control pHIL-S1 vector. (B) Non-reducing SDS-PAGE analysis. Electrophoretic pattern of non-reduced SDS-PAGE was the same as
that of reduced, indicating that the 2 fragments interacted in a non-covalent manner. (C) Primary structure of Sap7. Sap7 was separated into 2
fragments: Fragment 1 was a 52-kDa subunit composed of A144-G440; fragment 2 was a 15-kDa subunit composed of A441-E588. (D) Sensitivity of
proteolytic activity to major protease inhibitors. Proteolytic activity was measured using the FRETS-25Ala library with or without various protease
inhibitors. While the activity of Sap4 was completely inhibited by pepstatin A, Sap7 did not show sensitivity to any protease inhibitors used here.
Averages of at least 3 independent experiments are plotted, and the error bars show S.E.M. ** P,0.01 determined by the Tukey’s test after a
significant one-way factorial ANOVA (P,0.01), n.s.; not significant.
doi:10.1371/journal.pone.0032513.g001
Sap7 Is Insensitive to Pepstatin A
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fluorescence-quenched peptide substrates, and proteolytic activity
of Sap7 was determined by measuring the fluorescence increase
[29,30]. Sap7 exhibited significant proteolytic activity, while the
control showed no proteolytic activity (Fig. 1D). This result
indicated that proteolytic activity was not derived from contam-
ination by the proteases from P. pastoris. Surprisingly, Sap7 was not
inhibited by pepstatin A and any other protease inhibitors such as
EDTA, leupeptin, and PMSF. Under identical reaction condi-
tions, the proteolytic activity of Sap4 was completely inhibited by
pepstatin A (Fig. 1D).
Identification of the active site of Sap7
To eliminate the possibility that Sap7 was not an aspartic
protease, the protein sequences of Sap7 and its homologous
proteases, Sap1–3, were compared using CLUSTAL W (Fig. 2). It
was noted that 2 aspartic acid active site residues of Sap1–3 were
also conserved in the protein sequence of Sap7. To determine
Figure 2. Protein sequence alignment between Sap1–3 and Sap7. Multiple-sequence alignments were performed with CLUSTAL W. The
active site of Sap7 was predicted to be D244 and D464 by homology. The cleavage point of Sap7 was found in the Sap7-specific insertion sequence
N422-N451, which did not exist in the sequences of Sap1–3.
doi:10.1371/journal.pone.0032513.g002
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mutants in which these aspartic acids were substituted by alanine
were constructed by the QuikChange site-directed mutagenesis
technique. SDS-PAGE analysis showed that the D244A and
D464A mutants lost a 15-kDa band found in the lane of wild type
Sap7 (Fig. 3A). Furthermore, the mutants had no proteolytic
activity (Fig. 3B). These results suggest that D244 and D464 form
the active site of Sap7, and that the appearance of the 15-kDa
band is caused by self-processing of active Sap7.
Influence of N-glycosylation and fragmentation of Sap7
on pepstatin A-insensitivity
We identified 2 distinctive properties of Sap7 compared to
other Sap isozymes, and hypothesized that these could be
responsible for pepstatin A insensitivity of Sap7. One was the
highly, heterogeneously glycosylated form of Sap7. This
modification of carbohydrate chains on the protein surface
could act as a barrier to pepstatin A. The other was the
fragmentation of Sap7. The 2 catalytic aspartic acids were
separated into 2 fragments, and were found at the interface. If
the interaction between these fragments was weak, pepstatin A
could not form a stable bond with Sap7. To verify the first
hypothesis, the protease activity of Sap7 was measured after
EndoH treatment, which eliminated all N-glycosylation.
However, we observed no significant differences in the
proteolytic activity and pepstatin A-insensitivity of Sap7 with
or without EndoH (Fig. 4A). This result indicated that N-
glycosylation did not affect pepstatin A-insensitivity. For the
second hypothesis, we constructed a mutant, which prevented
the intramolecular fragmentation. We found that the fragmen-
tation point of Sap7 was located at the center of a Sap7-specific
sequence, N422–N451 (Fig. 1C and Fig. 2). To determine
whether this sequence was required for fragmentation, a
Sap7D422–451 mutant was constructed. SDS-PAGE analysis
Figure 3. D244A and D464A mutants possess no proteolytic activity. (A) SDS-PAGE analysis with or without EndoH treatment. The D244A
and D464A mutants prevented fragmentation, and lost the 15-kDa fragment found in the Sap7 wild type lane. M: marker. (B) Proteolytic activity of
the mutants. The D244A and D464A mutants completely lost their proteolytic activity. This result suggests that D244 and D464 represent the active
site of Sap7. Averages of at least 3 independent experiments are plotted, and the error bars are shown as 6S.E.M. ** P,0.01 determined by Tukey’s
test after a significant one-way factorial ANOVA (P,0.01).
doi:10.1371/journal.pone.0032513.g003
Figure 4. N-glycosylation and fragmentation of Sap7 did not affect its insensitivity to pepstatin A. (A) Proteolytic activity of
deglycosylated Sap7. The influence of N-glycosylation on its insensitivity to pepstatin A was evaluated by EndoH treatment. Deglycosylated Sap7 did
not show any significant change in proteolytic activity and pepstatin A insensitivity. (B) SDS-PAGE analysis of Sap7D422–451 with or without EndoH
treatment. The sum of the 52-kDa and 15-kDa wild type fragments (Fig. 1A) was almost equal to the 68-kDa fragment of Sap7D422–451, indicating
that Sap7D422–451 existed in a non-fragmented form. M: marker. (C) Proteolytic activity of Sap7D422–451. Sap7D422–451 was insensitive to
pepstatin A. Thus, there was no relationship between the fragmentation of Sap7 and pepstatin A insensitivity. The data represent the average of at
least 3 independent experiments. Error bars are shown as 6S.E.M. n.s.; not significant by Tukey’s test.
doi:10.1371/journal.pone.0032513.g004
Sap7 Is Insensitive to Pepstatin A
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treatment (Fig. 4B); the approximate sum of the 52-kDa and
15-kDa wild type fragments (Fig. 1A). Thus, a Sap7 mutant
without fragmentation was successfully constructed. On mea-
surement, the proteolytic activity of the mutant was found to be
insensitive to pepstatin A (Fig. 4C). As a result, the
fragmentation of Sap7 was determined to be unrelated to
pepstatin A insensitivity.
Determination of important amino acids for pepstatin A
insensitivity
Next, we tested the hypothesis that amino acid residues in close
proximity to the active site inhibited pepstatin A access. To verify
this hypothesis, the tertiary structure of Sap7 was calculated using
SWISS-MODEL based on the crystal structure of Sap2, which has
a homologous protein sequence with Sap7 [26] (Fig. 5). In the
previous section, we demonstrated that fragmentation had no
effect on Sap7 activity (Fig. 4), and therefore, in the model, we
calculated the tertiary structure of Sap7 as a non-fragmented
protein. The calculated structure is expected to reflect the native
folding of fragmented Sap7. Amino acids within 3 A ˚ of D244 and
D464 (shown in blue and green, respectively) were calculated using
the Pymol program, and identified to be M242, I243, T245,
G246, S247, L463, T465, G466, and T467. Each amino acid
within 3 A ˚ of the catalytic residues was substituted by alanine. All
the mutants were successfully produced by P. pastoris (Fig. 6A), and
we found that the proteolytic activities of the M242A and T467A
mutants were inhibited by pepstatin A (Fig. 6B). Interestingly,
T467A showed higher proteolytic activity than the wild type.
M242 and T467 are located at the entrance to the active site
(Fig. 7), and their side chains partially cover the entrance. As
compared to the wild type, the M242A and T467A mutants had
relatively wider entrances, because alanine has a side chain smaller
than that of methionine and threonine. This alteration might allow
pepstatin A to enter the active site.
Discussion
In this study, we used the P. pastoris expression system and
FLAG-tag affinity purification to purify Sap7, because C. albicans
has never produced Sap7 in vitro [31]. SAP7 is found to be
expressed by C. albicans in vivo [32]; however, it is difficult to purify
sufficient amounts of Sap7 under such conditions. The P. pastoris
expression system enabled us to obtain large quantities of Sap
isozymes for determining various enzymatic parameters. In
addition, protein folding by the P. pastoris expression system
reflects that of C. albicans [9,33]. Indeed, other Sap isozymes
produced by P. pastoris have been shown to have very similar
properties to those produced by C. albicans.
Interestingly, in our study, Sap7 was not inhibited by pepstatin
A (Fig. 1D). Pepstatin A is a potent inhibitor of almost all types of
aspartic proteases, and has been used to evaluate the virulence of
the Sap family [26,34,35]. Previously, a family of pepstatin A-
insensitive acid proteases was identified, which had originally been
characterized as aspartic proteases [36,37]. These proteases are
now known as glutamic proteases that use glutamic acid as the
catalytic residue instead of aspartic acid. To determine whether
Sap7 is actually an aspartic protease, we carried out a sequence
alignment between Sap7 and Sap1–3, and found that 2 catalytic
aspartic acids of Sap1–3 were also conserved in Sap7 (Fig. 2).
Alanine substitution in these amino acids led to the loss of the
proteolytic activity of Sap7 (Fig. 3B), indicating that Sap7 is not a
glutamic protease, but an aspartic protease. Thus, we propose that
the pepstatin A insensitivity of Sap7 is because of a novel
mechanism.
Our results showed that Sap7 has 2 important distinctive
characteristics: high N-glycosylation and intramolecular fragmen-
tation. These properties are thought not to be artifacts, but rather
inherent in Sap7 itself. The mechanism of N-glycosylation of P.
pastoris somewhat differs from that of C. albicans [38]; however, the
N-glycosylation pattern of the proteins heterogeneously produced
by P. pastoris is consistent with that observed in the proteins from C.
albicans [22,33,39]. The intramolecular fragmentation of Sap7 was
dependent on the Sap7-specific N422–N451 sequence (Fig. 2), and
did not occur in the D244A and D464A mutants, which possessed
no proteolytic activity (Fig. 3A). These observations indicate that
fragmentation is an intrinsic property of Sap7, and not due to P.
pastoris proteases. We assessed whether these distinct properties
affected pepstatin A insensitivity, and found no correlation (Fig. 4).
Figure 5. Structure of Sap7 calculated by SWISS-MODEL. The structure of Sap7 was calculated using SWISS-MODEL based on the crystal
structure of Sap2 (1eag), and visualized using Pymol. Red: D244 and D464, green: amino acids within 3 A ˚ of D244, blue: amino acids within 3 A ˚ of
D464, pale yellow: fragment 1, orange: fragment 2, and pink: N422–N451.
doi:10.1371/journal.pone.0032513.g005
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MODEL to test the hypothesis that amino acids in close proximity
to the active site inhibited pepstatin A access. We identified 9
amino acids, namely, M242, I243, T245, G246, S247, L463,
T465, G466, and T467, within 3 A ˚ from the active site (Fig. 5),
and found that the M242A mutant was strongly inhibited and the
T467 mutant was completely inhibited by pepstatin A (Fig. 6B).
Some of the other alanine substitution mutants showed little
proteolytic activity, probably because these residues were essential
to form the proper active site structure required to catalyze the
hydrolysis of the FRETS-25Ala library.
To understand why the M242A and T467A mutants were
sensitive to pepstatin A, we calculated the surface structure of Sap7
(Fig. 7). M242 and T467 were located on the surface of the
entrance to the active site, and the alanine substitution widened
the entrance. This alteration might increase the accessibility of
pepstatin A to the active site. Proteolytic activity of the T467A
mutant was completely inhibited by pepstatin A; thus, the entrance
was thought to be wider than that in wild type Sap7 and the
M242A mutant. This hypothesis was supported by the observation
that the T467A mutant had higher proteolytic activity than wild
type Sap7, indicating easy access of the substrate to the center
(Fig. 6B). T467 is a conserved amino acid between Sap1–3 and
Sap7, and therefore, it was assumed that Sap7 controlled the
accessibility of pepstatin A by a coupling effect between T467 and
other amino acids.
Similar to Sap7, Sap9 and Sap10 are suggested to be less
sensitive to pepstatin A [40]. The reason why C. albicans evolved
Figure 6. M242 and T467 are important amino acids in restricting the accessibility of pepstatin A to the active site. (A) SDS-PAGE
analysis of alanine substitution mutants with or without EndoH treatment. All mutants were successfully produced by P. pastoris, and a 15-kDa band
was confirmed in all samples. M: marker. (B) Proteolytic activity with or without pepstatin A. After pepstatin A treatment, M242A showed some
proteolytic activity, while T467A showed none. Relative activity of the T467A mutant was significantly stronger than that of wild type. Average of at
least 3 independent experiments are plotted, and the error bars are shown as 6S.E.M. ** P,0.01 determined by Tukey’s test after a significant one-
way factorial ANOVA (P,0.01).
doi:10.1371/journal.pone.0032513.g006
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remains to be clarified. It is possible that they are countermeasures
against natural aspartic protease inhibitors.
Many reports showed that Sap-deficient mutants attenuate
virulence and administration of pepstatin A inhibits various forms
of candidiasis [9,21,41,42,43,44]. Thus, it is evident that Sap
isozymes have important roles in the infectious process. However,
some reports suggested that Sap isozymes had a little effect on
some infection models because pepstatin A showed a little
protective effect [1,45,46,47,48]. Pepstatin A-insensitive Sap
isozymes including Sap7, Sap9, and Sap10 may have a partial
role to compensate for the reduced activities of other Sap isozymes
by pepstatin A.
In conclusion, we found that Sap7 was a pepstatin A-insensitive
protease, and that M242 and T467 restricted the accessibility of
pepstatin A to the active site. Based on the calculated structure of
pepstatin A-insensitive Saps, a novel protease inhibitor capable of
inhibiting the whole Sap family could be designed.
Supporting Information
Table S1 Primers used in this study. The desired mutation
is shown in red characters in the mutagenic oligonucleotide
primers.
(XLS)
Author Contributions
Conceived and designed the experiments: WA NM HM KK MU.
Performed the experiments: WA NK YY. Analyzed the data: WA YY.
Contributed reagents/materials/analysis tools: HM YY. Wrote the paper:
WA KK MU.
References
1. Naglik JR, Challacombe SJ, Hube B (2003) Candida albicans secreted aspartyl
proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67: 400–428.
2. Sobel JD (1992) Pathogenesis and treatment of recurrent vulvovaginal
candidiasis. Clin Infect Dis 14: 148–153.
3. Sobel JD (1988) Pathogenesis and epidemiology of vulvovaginal candidiasis.
Ann N Y Acad Sci 544: 547–557.
4. Schaller M, Borelli C, Korting HC, Hube B (2005) Hydrolytic enzymes as
virulence factors of Candida albicans. Mycoses 48: 365–377.
5. Calderone RA, Fonzi WA (2001) Virulence factors of Candida albicans. Trends
Microbiol 9: 327–335.
6. Naglik J, Albrecht A, Bader O, Hube B (2004) Candida albicans proteinases and
host/pathogen interactions. Cell Microbiol 6: 915–926.
7. Schaller M, Januschke E, Schackert C, Woerle B, Korting HC (2001) Different
isoforms of secreted aspartyl proteinases (Sap) are expressed by Candida albicans
during oral and cutaneous candidosis in vivo. J Med Microbiol 50: 743–747.
8. White TC, Miyasaki SH, Agabian N (1993) Three distinct secreted aspartyl
proteinases in Candida albicans. J Bacteriol 175: 6126–6133.
9. Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M (1998) The
expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans
in murine macrophages. Mol Microbiol 28: 543–554.
10. Taylor BN, Hannemann H, Sehnal M, Biesemeier A, Schweizer A, et al. (2005)
Induction of SAP7 correlates with virulence in an intravenous infection model of
candidiasis but not in a vaginal infection model in mice. Infect Immun 73:
7061–7063.
11. Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, et al. (2008)
Quantitative expression of the Candida albicans secreted aspartyl proteinase gene
family in human oral and vaginal candidiasis. Microbiology 154: 3266–3280.
12. Monod M, Hube B, Hess D, Sanglard D (1998) Differential regulation of SAP8
and SAP9, which encode two new members of the secreted aspartic proteinase
family in Candida albicans. Microbiology 144: 2731–2737.
13. Albrecht A, Felk A, Pichova I, Naglik JR, Schaller M, et al. (2006)
Glycosylphosphatidylinositol-anchored proteases of Candida albicans target
proteins necessary for both cellular processes and host-pathogen interactions.
J Biol Chem 281: 688–694.
14. Schild L, Heyken A, de Groot PW, Hiller E, Mock M, et al. (2011) Proteolytic
cleavage of covalently linked cell wall proteins by Candida albicans Sap9 and
Sap10. Eukaryot Cell 10: 98–109.
15. Hornbach A, Heyken A, Schild L, Hube B, Loffler J, et al. (2009) The
glycosylphosphatidylinositol-anchored protease Sap9 modulates the interaction
of Candida albicans with human neutrophils. Infect Immun 77: 5216–5224.
16. Colina AR, Aumont F, Deslauriers N, Belhumeur P, de Repentigny L (1996)
Evidence for degradation of gastrointestinal mucin by Candida albicans secretory
aspartyl proteinase. Infect Immun 64: 4514–4519.
17. Kaminishi H, Miyaguchi H, Tamaki T, Suenaga N, Hisamatsu M, et al. (1995)
Degradation of humoral host defense by Candida albicans proteinase. Infect
Immun 63: 984–988.
18. Ruchel R (1986) Cleavage of immunoglobulins by pathogenic yeasts of the genus
Candida. Microbiol Sci 3: 316–319.
19. Gropp K, Schild L, Schindler S, Hube B, Zipfel PF, et al. (2009) The yeast
Candida albicans evades human complement attack by secretion of aspartic
proteases. Mol Immunol 47: 465–475.
20. Villar CC, Kashleva H, Nobile CJ, Mitchell AP, Dongari-Bagtzoglou A (2007)
Mucosal tissue invasion by Candida albicans is associated with E-cadherin
degradation, mediated by transcription factor Rim101p and protease Sap5p.
Infect Immun 75: 2126–2135.
21. Schaller M, Bein M, Korting HC, Baur S, Hamm G, et al. (2003) The secreted
aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of
vaginal candidiasis based on reconstituted human vaginal epithelium. Infect
Immun 71: 3227–3234.
22. Aoki W, Kitahara N, Miura N, Morisaka H, Yamamoto Y, et al. (2011)
Comprehensive characterization of secreted aspartic proteases encoded by a
virulence gene family in Candida albicans. J Biochem 150: 431–438.
23. Berman J, Sudbery PE (2002) Candida albicans: a molecular revolution built on
lessons from budding yeast. Nat Rev Genet 3: 918–930.
24. Arnaud MB, Costanzo MC, Skrzypek MS, Binkley G, Lane C, et al. (2005) The
Candida Genome Database (CGD), a community resource for Candida albicans
gene and protein information. Nucleic Acids Res 33: 358–363.
25. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic
Acids Res 22: 4673–4680.
26. Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, et al. (1995)
The crystal structure of a major secreted aspartic proteinase from Candida albicans
in complexes with two inhibitors. Structure 3: 1261–1271.
27. Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL
workspace: a web-based environment for protein structure homology modelling.
Bioinformatics 22: 195–201.
28. Laskowski RA (2009) PDBsum new things. Nucleic Acids Res 37: 355–359.
29. Tanskul S, Oda K, Oyama H, Noparatnaraporn N, Tsunemi M, et al. (2003)
Substrate specificity of alkaline serine proteinase isolated from photosynthetic
bacterium, Rubrivivax gelatinosus KDDS1. Biochem Biophys Res Commun 309:
547–551.
30. Aoki W, Kitahara N, Miura N, Morisaka H, Yamamoto Y, et al. (2011)
Comprehensive characterization of secreted aspartic proteases encoded by a
virulence gene family in Candida albicans. J Biochem 150: 431–438.
Figure 7. Surface modeling of Sap7. The surface structure of WT
Sap7 was calculated using SWISS-MODEL based on the crystal structure
of Sap2 (1eag), and visualized using Pymol. M242 and T467 were
located near the entrance to the active site. Red: D244 and D464, green:
M242, blue: T467, pale yellow: fragment 1, orange: fragment 2, and
pink: N422–N451.
doi:10.1371/journal.pone.0032513.g007
Sap7 Is Insensitive to Pepstatin A
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e3251331. Hube B, Sanglard D, Odds FC, Hess D, Monod M, et al. (1997) Disruption of
each of the secreted aspartyl proteinase genes SAP1, SAP2,a n dSAP3 of Candida
albicans attenuates virulence. Infect Immun 65: 3529–3538.
32. Naglik JR, Newport G, White TC, Fernandes-Naglik LL, Greenspan JS, et al.
(1999) In vivo analysis of secreted aspartyl proteinase expression in human oral
candidiasis. Infect Immun 67: 2482–2490.
33. Smolenski G, Sullivan PA, Cutfield SM, Cutfield JF (1997) Analysis of secreted
aspartic proteinases from Candida albicans: purification and characterization of
individual Sap1, Sap2 and Sap3 isoenzymes. Microbiology 143: 349–356.
34. Marciniszyn J, Jr., Hartsuck JA, Tang J (1976) Mode of inhibition of acid
proteases by pepstatin. J Biol Chem 251: 7088–7094.
35. Marciniszyn J, Jr., Hartsuck JA, Tang J (1977) Pepstatin inhibition mechanism.
Adv Exp Med Biol 95: 199–210.
36. Fujinaga M, Cherney MM, Oyama H, Oda K, James MN (2004) The molecular
structure and catalytic mechanism of a novel carboxyl peptidase from Scytalidium
lignicolum. Proc Natl Acad Sci U S A 101: 3364–3369.
37. Sims AH, Dunn-Coleman NS, Robson GD, Oliver SG (2004) Glutamic protease
distribution is limited to filamentous fungi. FEMS Microbiol Lett 239: 95–101.
38. Gemmill TR, Trimble RB (1999) Overview of N-a n dO-linked oligosaccharide
structures found in various yeast species. Biochim Biophys Acta 1426: 227–237.
39. Chen YC, Wu CC, Chung WL, Lee FJ (2002) Differential secretion of Sap4-6
proteins in Candida albicans during hyphae formation. Microbiology 148:
3743–3754.
40. Schild L, Heyken A, de Groot PW, Hiller E, Mock M, et al. (2011) Proteolytic
cleavage of covalently linked cell wall proteins by Candida albicans Sap9 and
Sap10. Eukaryot Cell 10: 98–109.
41. Fallon K, Bausch K, Noonan J, Huguenel E, Tamburini P (1997) Role of
aspartic proteases in disseminated Candida albicans infection in mice. Infect
Immun 65: 551–556.
42. De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, et al. (1997)
Protective role of antimannan and anti-aspartyl proteinase antibodies in an
experimental model of Candida albicans vaginitis in rats. Infect Immun 65:
3399–3405.
43. Hube B (1998) Possible role of secreted proteinases in Candida albicans infections.
Rev Iberoam Micol 15: 65–68.
44. Sanglard D, Hube B, Monod M, Odds FC, Gow NA (1997) A triple deletion of
the secreted aspartyl proteinase genes SAP4, SAP5,a n dSAP6 of Candida albicans
causes attenuated virulence. Infect Immun 65: 3539–3546.
45. Odds FC (2008) Secreted proteinases and Candida albicans virulence. Microbi-
ology 154: 3245–3246.
46. Lermann U, Morschhauser J (2008) Secreted aspartic proteases are not required
for invasion of reconstituted human epithelia by Candida albicans. Microbiology
154: 3281–3295.
47. Kretschmar M, Felk A, Staib P, Schaller M, Hess D, et al. (2002) Individual acid
aspartic proteinases (Saps) 1–6 of Candida albicans are not essential for invasion
and colonization of the gastrointestinal tract in mice. Microb Pathog 32: 61–70.
48. Edison AM, Manning-Zweerink M (1988) Comparison of the extracellular
proteinase activity produced by a low-virulence mutant of Candida albicans and its
wild-type parent. Infect Immun 56: 1388–1390.
Sap7 Is Insensitive to Pepstatin A
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32513